Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood markers may help predict heart trouble in diabetes patients

NCT ID NCT07362953

Knowledge-focused Sponsor: Tokat Gaziosmanpasa University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 2188 adults with type 2 diabetes or prediabetes to see if three simple blood test scores could predict heart and metabolic risk. The researchers calculated the triglyceride-glucose index, atherogenic plasma index, and systemic immune-inflammation index from routine lab results. No treatment was given; the goal was to find better ways to identify high-risk patients early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,188 people

The number who actually took part.

Started

Mar 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with a confirmed diagnosis of type 2 diabetes mellitus or prediabetes attending the Department of Internal Medicine at Tokat Gaziosmanpaşa University Hospital during the study period will constitute the study population. Enrollment will be limited to individuals who meet the eligibility criteria and provide written informed consent.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Having a diagnosis of T2DM * Having a diagnosis of prediabetes * Being between 18 and 65 years of age. Exclusion Criteria: * Having any other chronic disease accompanying T2DM/prediabetes * Receiving hormone therapy * Using lipid-lowering agents * Being pregnant/breastfeeding * Having an acute infection * Having any malignant/inflammatory disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemia associated with type II diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemia associated with type II diabetes mellitus

Contacts and locations

Locations

  • Tokat Gaziosmanpaşa University Health Research and Application Hospital

    Tokat Province, 60250, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.